X4 Pharmaceuticals, Inc.

In 2024, the FDA approved over 130 drugs, including 40 novel ones. Madrigal's Rezdiffra is the first treatment for MASH, X4's Xolremdi for WHIM syndrome, Day One's Ojemda for pediatric low-grade glioma, Geron's Rytelo for MDS, and ImmunityBio's Anktiva for NMIBC. These approvals mark significant milestones for these companies and address high unmet medical needs.

X4 Pharmaceuticals reports positive Phase 2 results for mavorixafor in chronic neutropenia, with Phase 3 4WARD trial on track for mid-2025 enrollment. U.S. launch of XOLREMDI® (mavorixafor) for WHIM syndrome underway, with EMA MAA submission expected by early 2025.

Researchers at Fred Hutch Cancer Center identify SLC35A2 protein favoring R5 HIV-1 variants over X4, potentially aiding vaccine development.